JP2024529185A - ラジプロジルの製剤化 - Google Patents

ラジプロジルの製剤化 Download PDF

Info

Publication number
JP2024529185A
JP2024529185A JP2024532367A JP2024532367A JP2024529185A JP 2024529185 A JP2024529185 A JP 2024529185A JP 2024532367 A JP2024532367 A JP 2024532367A JP 2024532367 A JP2024532367 A JP 2024532367A JP 2024529185 A JP2024529185 A JP 2024529185A
Authority
JP
Japan
Prior art keywords
composition
weight
total weight
compound
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529185A5 (https=
Inventor
ジェニン，マリー
マグリア，ピエランドリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grin Therapeutics Inc
Original Assignee
Grin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grin Therapeutics Inc filed Critical Grin Therapeutics Inc
Publication of JP2024529185A publication Critical patent/JP2024529185A/ja
Publication of JP2024529185A5 publication Critical patent/JP2024529185A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024532367A 2021-08-06 2022-08-05 ラジプロジルの製剤化 Pending JP2024529185A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163230331P 2021-08-06 2021-08-06
US63/230,331 2021-08-06
PCT/US2022/039543 WO2023014956A1 (en) 2021-08-06 2022-08-05 Formulations of radiprodil

Publications (2)

Publication Number Publication Date
JP2024529185A true JP2024529185A (ja) 2024-08-01
JP2024529185A5 JP2024529185A5 (https=) 2025-08-14

Family

ID=83189017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532367A Pending JP2024529185A (ja) 2021-08-06 2022-08-05 ラジプロジルの製剤化

Country Status (12)

Country Link
US (2) US20250127770A1 (https=)
EP (1) EP4380547A1 (https=)
JP (1) JP2024529185A (https=)
KR (1) KR20240052765A (https=)
CN (1) CN118019521A (https=)
AU (1) AU2022323381A1 (https=)
CA (1) CA3228004A1 (https=)
CO (1) CO2024002715A2 (https=)
IL (1) IL310652A (https=)
MX (1) MX2024001744A (https=)
PE (1) PE20241385A1 (https=)
WO (1) WO2023014956A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137652A2 (en) * 2023-12-20 2025-06-26 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2453383C (en) 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Piperidine derivatives as nmda receptor antagonists
CA2730253A1 (en) * 2008-07-08 2010-01-14 Alphonso Higuera Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
AU2009282822A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating CNS disorders
HUP0900130A3 (en) * 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US8328687B2 (en) 2010-07-09 2012-12-11 Ford Global Technologies, Llc Method for controlling an engine that may be automatically stopped

Also Published As

Publication number Publication date
CO2024002715A2 (es) 2024-05-20
IL310652A (en) 2024-04-01
US20250127770A1 (en) 2025-04-24
WO2023014956A1 (en) 2023-02-09
AU2022323381A1 (en) 2024-03-21
KR20240052765A (ko) 2024-04-23
EP4380547A1 (en) 2024-06-12
US20260053786A1 (en) 2026-02-26
PE20241385A1 (es) 2024-07-09
CA3228004A1 (en) 2023-02-09
WO2023014956A9 (en) 2023-12-14
CN118019521A (zh) 2024-05-10
MX2024001744A (es) 2024-04-23

Similar Documents

Publication Publication Date Title
EP1511481B1 (en) Ophthalmological use of roflumilast for the treatment of diseases of the eye
EP2258394B1 (en) Oral dosage form comprising a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US20070264330A1 (en) Pharmaceutical formulations of pimavanserin
EP2214637B1 (en) Stabilized pediatric suspension of carisbamate
TW201418245A (zh) 醫藥組合物
EP2749270B1 (en) Racecadotril and pharmaceutical compositions thereof
US20260053786A1 (en) Formulations of radiprodil
EP3302477B1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
EP2563340A2 (en) Water soluble pharmaceutical composition
EP2646434B1 (en) Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
NZ224497A (en) Pharmaceutical composition comprising flunarizine
AU2022425382A1 (en) Pharmaceutical composition
EP2515850B1 (en) Pharmaceutical compositions comprising cefdinir as an active agent
US10183018B2 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US11241424B2 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
MX2013012827A (es) Composicion oral liquida que comprende sodio divalproex y proceso para la preparar la misma.
US20200030318A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
WO2016114734A1 (en) Pharmaceutical formulation of trimebutine maleate and simethicone comprising acidifying agent
US20260090985A1 (en) Oral mucosal formulations of aspirin
EP4180042A1 (en) A film coated tablet comprising micronized tofacitinib
CA3238703A1 (en) A film coated tablet comprising micronized tofacitinib
EP2441438A1 (en) Sachet formulations of eslicarbazepine
CN118742300A (zh) 药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250805

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260410

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260410